Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Lee Schwartzberg MD, FACP
Lee S. Schwartzberg MD, FACP Advisory Board
Alexander van Akkooi MD, PhD, FRACS
Alexander C. J. van Akkooi MD, PhD, FRACS Associate Editor
Barbara Burtness MD
Barbara Burtness MD Advisory Board
See All Experts
featured
Published in Oncology

Expert Opinion / Commentary · December 12, 2024

2024 Top Story in Oncology: DESTINY-Breast06 — TDX-d for HR+/HER2-Low or HER2 Ultra–Low Breast Cancer After Prior Endocrine Therapy

Jeffrey Kirshner MD, FACP, FASCO

 

 Save  Recommend
 Share

Additional Info

Further Reading

Most Read This Week

Recently Updated